OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
September 13, 2005
A look at the science behind a new class of rheumatoid arthritis drugs that act by suppressing an early stage of inflammation, the activation of T cells.
A University of California San Diego professor explains the results of his research on nuclear receptors and why these findings could lead to new therapies for autoimmune diseases.
Analysis of a new report that says safety-related product withdrawals have not increased since the approval process sped up in the 1990s.